Status:
UNKNOWN
Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis
Lead Sponsor:
University of Leipzig
Conditions:
Heart Failure NYHA Class II
Heart Failure NYHA Class III
Eligibility:
All Genders
60+ years
Brief Summary
The study aims to test the diagnostic accuracy of native T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that native T1 mapping with a cut-off value of 1341ms (3 t...
Detailed Description
Cardiac amyloidosis (CA) is an important differential diagnosis in older patients with symptomatic heart failure with preserved or mid-range ejection fraction and increased left ventricular wall thick...
Eligibility Criteria
Inclusion
- Age ≥ 60 years
- Symptomatic heart failure (NYHA II-IV) with LVEF ≥40%
- Increased LV wall thickness (≥12mm end-diastolic)
- NT-proBNP ≥1000pg/mL
- Elevated hs-troponin T ≥14ng/L
Exclusion
- Contraindications for CMR
- Acute myocarditis
- Acute myocardial infarction \<1 month
- Severe aortic stenosis and RAISE score \< 2 points
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT04862273
Start Date
April 1 2021
End Date
November 1 2024
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Leipzig
Leipzig, Saxony, Germany, 04103